Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• In 2025, Teva expects its generics business to be flat to up in low single digits in constant currency terms

  80% confidence

• Teva anticipates generating more than $5 billion in revenues from its branded products by 2030

  80% confidence

• Austedo annual revenues expected to be more than $2.5 billion by 2027

  80% confidence

• Teva is a Hold stock with Zacks Rank #3

  80% confidence

• Teva expects an adjusted operating margin of 30% by 2027 through cost savings and continued growth of branded drugs

  80% confidence

• Teva expects to launch Austedo in European markets in 2026

  80% confidence

• The outcome of the IRA pricing negotiations for Austedo went as expected

  80% confidence

• Teva raised its 2025 Austedo sales expectations following IRA pricing negotiations conclusion

  80% confidence

• Teva expects Uzedy total sales to be between $190 million and $200 million in 2025

  80% confidence

• Teva aims to double its global biosimilars sales by 2027

  80% confidence

• CMS is expected to formally announce the agreement on a maximum fair price for Austedo in November 2025

  80% confidence

• Austedo sales expected to exceed $3 billion by 2030

  80% confidence

• Teva expects to file a new drug application for olanzapine before the year ends

  80% confidence

• Teva expects five additional biosimilar launches by 2027

  80% confidence